| 31 |
Co-morbidity Management |
Pending Review |
09/01/2022 |
| 73 |
Impact of COVID-19 on TB Elimination Efforts |
Pending Review |
09/01/2022 |
| 69 |
Specimen Collection for Diagnosis |
Pending Review |
09/01/2022 |
| 71 |
Specimen Receipt |
Pending Review |
09/01/2022 |
| 72 |
Specimen collection and transportation documentation |
Pending Review |
09/01/2022 |
| 67 |
Tests for TB infection |
Pending Review |
09/01/2022 |
| 68 |
Serological Tests [Banned] |
Pending Review |
09/01/2022 |
| 65 |
Radiological Images |
Pending Review |
09/01/2022 |
| 66 |
Histopathological Tests |
Pending Review |
09/01/2022 |
| 19 |
Operational Definitions in Case Finding |
Live |
09/01/2022 |
| 43 |
Partnerships |
Pending Review |
09/01/2022 |
| 45 |
TB Surveillance |
Pending Review |
09/01/2022 |
| 48 |
Evaluation |
Pending Review |
09/01/2022 |
| 49 |
Direct Benefit Transfer and financial enablers |
Pending Review |
09/01/2022 |
| 36 |
Principles of ACSM in NTEP |
Pending Review |
09/01/2022 |
| 37 |
Structures for ACSM under NTEP |
Pending Review |
09/01/2022 |
| 34 |
TB Vaccines |
Pending Review |
09/01/2022 |
| 35 |
Reducing TB Vulnerabilities |
Pending Review |
09/01/2022 |
| 27 |
Palliative Care and Rehabilitation |
Pending Review |
09/01/2022 |
| 8 |
History of TB |
Live |
06/01/2022 |
| 15 |
Discovery of Anti TB Drugs |
Pending Review |
06/01/2022 |